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Abstract
Background: Patients with TB have diverse and often challenging clinical and social needs that may hamper successful
treatment outcomes. Understanding the need for additional support during treatment (enhanced case management, or
ECM) is important for workforce capacity planning. North West England TB Cohort Audit (TBCA) has introduced a 4-level
ECM classification system (ECM 0–3) to quantify the need for ECM in the region. This study describes the data from the
first 2 years of ECM classification.
Methods: Data collected between April 2013 and July 2015 were used to analyse the proportions of patients allocated to
each ECM level and the prevalence of social and clinical factors indicating need for ECM. Single variable and multivariable
logistic regression models were constructed to examine the association between ECM level and treatment outcome.
Results: Of 1714 notified cases 99.8% were assigned an ECM level: 31% ECM1, 19% ECM2 and 14% ECM3. The
most common factors indicating need for ECM were language barriers (20.3%) and clinical complexity (16.9%).
1342/1493 (89.9%) of drug-sensitive, non-CNS cases completed treatment within 12 months. Patients in ECM2
and 3 were less likely to complete treatment at 12 months than patients in ECM0 (adjusted OR 0.47 [95% CI
0.27–0.84] and 0.23 [0.13–0.41] respectively).
Conclusions: Use of TBCA to quantify different levels of need for ECM is feasible and has demonstrated that
social and clinical complexity is common in the region. Results will inform regional workforce planning and
assist development of innovative methods to improve treatment outcomes in these vulnerable groups.
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Treatment completion
Background
Tuberculosis (TB) is an infectious airborne disease of
major global public health concern. It is estimated that in
2015 there were 10.4 million incident cases of TB result-
ing in 1.4 million deaths worldwide [1]. In England TB in-
cidence has declined by one third over the past 4 years to
a rate of 10.5 per 100,000 [2]. Despite this reduction the
TB notification rate in England remains higher than in
most other Western European countries [3] and more
than three times higher than in the USA [4]. Public Health
England has declared TB to be a national public health
priority area [5]. In the North West of England, although
overall TB notification rates are relatively low (7.9 per
100,000 in 2015), rates are high in urban centres such as
Manchester (27 per 100,000 3 year average 2013–2015) [2].
TB Cohort Audit (TBCA), sometimes referred to as
Cohort Review, is a systematic multidisciplinary review
of the management and outcomes of all TB cases in a
geographical area with the aim of improving clinical and
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public health outcomes and thereby strengthening the
prevention and control of TB [6, 7]. The National Institute
for Health and Care Excellence (NICE) has recommended
that TBCA should be included in TB prevention and con-
trol programmes since 2012 [8]. TBCA was first intro-
duced in the UK in London in 2010 and was implemented
in the North West in 2012 due to pockets of high inci-
dence in regional urban centres. North West TBCA meet-
ings bring together TB nurses, TB physicians, public
health professionals, epidemiologists and analysts to
review and discuss the management of each individual TB
case. Cases are reviewed approximately 6–9 months fol-
lowing treatment commencement, at or near the end of a
standard course of treatment. The process captures
detailed quantitative data and monitors outcome indica-
tors. In addition, presentation and discussion of cases in a
supportive environment provides a forum for training and
education of staff and for the identification of issues relat-
ing to case management, workforce or quality of care.
Completion of TB treatment is imperative from both a
clinical and public health perspective with failure to
complete increasing the risk of relapse, death, drug resist-
ance and disease transmission [9]. Although treatment is
highly effective and relatively inexpensive, the minimum
treatment duration of 6 months for non-resistant cases can
make it difficult for patients to fully adhere to the regimen
[10]. Standard Case Management (SCM) coordinated by a
named case manager, most often a specialist TB nurse, is
appropriate for non-clinically complex patients able to self-
medicate and have monthly follow-up in a hospital or com-
munity setting [11]. Cases with clinically and/or socially
complex needs require a higher level of support to ensure
successful treatment outcomes and for this reason the Na-
tional Institute for Health and Care Excellence (NICE) and
the Royal College of Nursing (RCN) recommend that such
cases should receive Enhanced Case Management (ECM)
[11, 12]. ECM is defined by NICE as care that “is provided
when someone has clinically or socially complex needs…As
part of ECM, the need for Directly Observed Treatment
(DOT) is considered, in conjunction with a package of sup-
portive care tailored to the person’s needs.” (8) These add-
itional care needs are commonly delivered by the named
case manager, usually the TB nurse, working alongside a
specialist multidisciplinary TB team.
Prior to the introduction of TBCA in the North West of
England there was no comprehensive way of quantifying the
need for ECM in the area. NICE recommend that TBCA
should be used to collect data on the numbers requiring
ECM in order to inform local needs assessments [12].
Quantification of these needs within a TB population will be
important for workforce planning, particularly relating to
TB nurse staffing levels. For this reason, in 2013, following
the pilot of TBCA in the North West, a series of enhanced
case management levels was introduced into TBCA ranging
from level 0 (standard case management) to level 3 (highest
level of enhanced case management) (Table 1). Patients now
undergo a standardised risk assessment and are assigned an
ECM level based on their clinical and social needs and
hence the level of input they required from the multidiscip-
linary team. This study aimed to quantify the ECM levels of
patients in the region, evaluate the prevalence of the under-
lying social and clinical factors indicating need for ECM,




Data collected from North West TBCA between April
2013, representing the introduction of the ECM classifica-
tion system into TBCA, and July 2015 were combined
with routine data from Public Health England’s Enhanced
TB Surveillance (ETS) system. All notified TB cases were
reviewed at TBCA in this period and were eligible for in-
clusion in the analysis. Cases that had not been assigned
an ECM level were excluded from the analysis.
Development of enhanced case management (ECM) levels
Definitions of ECM levels 0–3 were agreed based on
expert consensus between representatives from clin-
ical medicine, nursing and public health with ECM 0
representing SCM and ECM levels 1–3 representing
different levels of ECM (Table 1). A guide was pro-
duced to assist TB nurses in allocating patients to ap-
propriate ECM levels (Appendix) which aimed to
reflect the diverse nature of patient needs and the im-
pact these have on patient management. The ECM
levels were piloted as part of TBCA, discussed and
refined at TBCA meetings and subsequently finalised
by the North West TBCA Steering Committee. The
ECM classification system was formally introduced
into TBCA in April 2013. Risk factors for Enhanced
Case Management are evaluated by TB nurses at the
beginning of treatment to establish the level of sup-
port the patient will require from the multi-
disciplinary team and the ECM level is formalised
and agreed at the time of TBCA.
As part of ECM classification, data were collected
on specific factors indicating need for ECM including
language barrier, clinical complexity (which includes
those cases with renal impairment, HIV coinfection,
diabetes, drug resistance or severe side effects), being
in a hard-to-reach group (HTRG), non-adherence to
treatment, homelessness, alcohol dependency, drug
dependency, imprisonment, previous TB diagnosis and
mental health problems. Some key definitions used in
TBCA for ECM levels and factors indicating need for
ECM are given in Table 1.
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Statistical analysis
We performed a descriptive analysis to assess the propor-
tion of TB cases classified to each ECM level and examine
the prevalence of the recorded clinical and social indicators
for ECM. We then examined the association between ECM
level and treatment completion at 12 months. Single and
multivariable logistic regression analyses were performed
and multivariable models were adjusted a priori for age
group and gender followed by other demographic factors
found to be significantly associated with ECM level. Cases
with one or more drug resistance, CNS disease and post-
mortem diagnoses were excluded from the analysis as these
cases would not be expected to complete treatment within
12 months. The analysis was repeated after excluding all
patients with a language barrier documented as this is a
major indicator for ECM in the North West but this may
not be the case in other areas where demographic charac-
teristics of patients may differ and/or the TB nurses have
language skills relevant to the population served. All statis-
tical analyses were performed using Stata, Version 12 (Stata
Corp., College Station, Texas).
Ethics
This study used anonymised routinely collected public
health audit and surveillance data and individual partici-
pant assent was not sought. The North West TB Summit




During the study period, there were 1714 TB cases
reviewed at TBCA of whom 1711 (99.8%) had been
assigned an ECM level and were therefore included in the
analysis. The median age of included cases was 40 years
(interquartile range 28–57 years) and 999/1711 (58.4%) of
cases were male (Table 2). The majority of cases were non-
UK born (1077/1675, 64.3%) but amongst those in ECM
level 3 the majority of cases were UK born (128/241,
54.7%). Those of Pakistani and white ethnicity accounted
for over 60% of cases (564/1652 (34.1%) and 457/1652
(27.7%) respectively). Patients living in the most deprived
national index of multiple deprivation (IMD) quintile
accounted for 1027/1625 (63.2%) of cases and those living
in the least deprived quintile accounted for 92/1625
(5.7%) of cases. Nearly half the cases had pulmonary
disease (814/1711, 47.6%), of whom 335 (41%) were
sputum smear positive.
ECM classification and factors indicating need for ECM
1095/1711 (64%) patients were assessed as requiring some
level of Enhanced Case Management with 528/1711 (31%)
classified as level 1, 326/1711 (19%) as level 2 and 241/1711
(14%) as level 3. Level 0, or Standard Case Management,
accounted for 616/1711 (36%) of all cases (Table 2). Lan-
guage barrier was the most common recorded factor indi-
cating need for ECM (348/1711, 20.3%) followed by clinical
complexity (289/1711, 16.9%), non-adherence to treatment
(119/1711, 7.0%), previous TB diagnosis (95/1711, 5.6%), be-
ing from a HTRG (66/1711, 3.9%), and mental health prob-
lems (58/1711, 3.4%) (Table 3). Homelessness (45/1711,
2.6%), injecting drug use (50/1711, 2.9%), problem alcohol
use (53/1711, 3.1%) and imprisonment (53/1711, 3.1%) were
less common overall. The prevalence of all indictors in-
creased with higher ECM level with the exception of lan-
guage barrier which is most prominent in ECM 1 (Table 3).
ECM level and treatment outcome
1342/1493 (89.9%) of drug-sensitive, non-CNS cases
completed treatment within 12 months: 520/553 (94.0%)
in ECM 0, 439/481 (91.3%) in ECM 1, 237/269 (88.1%)
in ECM 2 and 146/190 (76.8%) in ECM 3. Increasing
ECM level was inversely associated with treatment com-
pletion at 12 months (Chi-square test for trend p <
0.001). Of drug resistant cases 46/71 (64.8%) completed
treatment within 12 months; 10/15 (66.7%) in ECM 0,
16/18 (88.9%) in ECM 1, 15/20 (75.0%) in ECM 2 and 5/
18 (27.8%) in ECM 3.
Table 1 Key definitions of variables used in TB Cohort Audit
Enhanced Case
Management
“Enhanced Case Management is provided when someone has clinically or socially complex needs. It commences as soon
as TB is suspected. As part of ECM, the need for Directly Observed Treatment (DOT) is considered, in conjunction with a
package of supportive care tailored to the person’s needs.” (12)
ECM level 0 Equivalent to Standard Case Management: no clinical or social issues impacting on treatment, ability to self-medicate and
have monthly follow-up in a hospital or community setting, no complex contact tracing requirements
ECM level 1 Clinical and/or social issues impacting on treatment and necessitating fortnightly visits
ECM level 2 Complex clinical and/or social issues impacting on treatment and necessitating weekly visits
ECM level 3 Very complex clinical and/or social issues impacting on treatment. May require directly observed treatment (DOT)
Clinically complex Clinically complex cases are those with one or more of: renal impairment, HIV co-infection, diabetes, drug resistance or
severe side-effects
Hard to reach group
(HTRG)
Children, young people and adults whose social circumstances or lifestyle, or those of their parents or carers, make it
difficult to: recognise the clinical onset of TB, access diagnostic and treatment services, self-administer treatment or attend
regular appointments for clinical follow-up
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Table 2 Demographic characteristics of TB cases in the North West of England by Enhanced Case Management level N = 1711
Independent variable Total (%) ECM Level P-value*
0 N = 616 (36%) 1 N = 528 (31%) 2 N = 326 (19%) 3 N = 241 (14%)
Age group (n = 1710a) <0.001
0–15 89 (5.2) 10 (1.6) 34 (6.5) 28 (8.6) 17 (7.1)
16–30 434 (25.4) 167 (27.1) 124 (23.5) 92 (28.2) 51 (21.2)
31–45 485 (28.4) 193 (31.3) 150 (28.5) 79 (24.2) 63 (26.1)
46–65 394 (23.0) 136 (22.1) 122 (23.2) 67 (20.6) 69 (28.6)
> 65 308 (18.0) 110 (17.9) 97 (18.4) 60 (18.4) 41 (17.0)
Gender (n = 1711) 0.85
Male 999 (58.4) 359 (58.3) 313 (59.3) 187 (57.4) 140 (58.1)
Female 712 (41.6) 257 (41.7) 215 (40.7) 139 (42.6) 101 (41.9)
Born in the UK (n = 1675a) <0.001
No 1077 (64.3) 427 (71.2) 349 (67.4) 195 (60.4) 106 (45.3)
Yes 598 (35.7) 173 (28.8) 169 (32.6) 128 (39.6) 128 (54.7)
Ethnic group (n = 1652a) <0.001
White 457 (27.7) 143 (24.2) 118 (23.1) 91 (28.8) 105 (44.9)
Pakistani 564 (34.1) 212 (35.8) 204 (40.0) 93 (29.4) 55 (23.5)
Indian 251 (15.2) 112 (18.9) 49 (9.6) 62 (19.6) 28 (12.0)
Black African 198 (12.0) 65 (11.0) 71 (13.9) 37 (11.7) 25 (10.7)
Bangladeshi 42 (2.5) 17 (2.9) 19 (3.7) 4 (1.3) 2 (0.9)
Otherb 140 (8.5) 43 (7.3) 49 (9.6) 29 (9.2) 19 (8.1)
Deprivation quintile (n = 1625a) <0.001
1 (least deprived) 92 (5.7) 46 (7.8) 21 (4.2) 12 (3.9) 13 (5.6)
2 120 (7.4) 64 (10.8) 26 (5.3) 19 (6.2) 11 (4.7)
3 148 (9.1) 67 (11.3) 44 (8.9) 16 (5.2) 21 (9.1)
4 238 (14.7) 96 (16.2) 65 (13.1) 44 (14.3) 33 (14.2)
5 (most deprived) 1027 (63.2) 318 (53.8) 339 (68.5) 216 (70.4) 154 (66.4)
aMissing data
bIncludes Black Caribbean, Black Other, Chinese and Mixed/Other
*P-value for differences across categories of ECM: Chi-square test for trend (dichotomous variables), Pearson’s Chi-square test (other categorical variables)
Table 3 Factors indicating need for ECM by ECM level
Indicator for ECM Total (%) ECM level
0 1 2 3
Language barrier 348 (20.3) 10 (1.62) 189 (35.8) 96 (29.5) 53 (22.0)
Clinically complex 289 (16.9) 7 (1.1) 70 (13.3) 106 (32.5) 106 (44.0)
Nonadherence to medication 119 (7.0) 2 (0.3) 14 (2.7) 25 (7.7) 78 (32.4)
HTRG 66 (3.9) 1 (0.2) 7 (1.3) 17 (5.2) 41 (17.0)
Previous TB diagnosis 95 (5.6) 27 (4.4) 24 (4.6) 17 (5.2) 27 (11.2)
Mental health problems 58 (3.4) 1 (0.2) 9 (1.7) 16 (4.9) 32 (13.3)
Problem alcohol use 53 (3.1) 2 (0.3) 5 (1.0) 10 (3.1) 36 (14.9)
Imprisonment 53 (3.1) 4 (0.7) 10 (1.9) 12 (3.7) 27 (11.2)
Injecting drug use 50 (2.9) 1 (0.2) 5 (1.0) 13 (4.0) 31 (12.9)
Homelessness 45 (2.6) 2 (0.3) 4 (0.8) 16 (4.9) 23 (9.5)
Drug resistance (one or more) 78 (4.6) 15 (2.4) 18 (3.4) 21 (6.4) 24 (10.0)
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On single variable analysis patients in ECM levels 2 and
3 were significantly less likely to complete treatment
within 12 months than patients in ECM level 0 (OR 0.47,
95% CI 0.28–0.78 and OR 0.21, 95% CI 0.13–0.34 respect-
ively). After adjustment for age group, gender, UK born
status, deprivation quintile and ethnic group on multivari-
able analysis patients in ECM 2 and 3 remained signifi-
cantly less likely to complete treatment in 12 months than
patients in ECM 0 (OR 0.47, 95% CI 0.27–0.84 and OR
0.23, 95% CI 0.13–0.41 respectively) (Table 4). When all
patients documented as having a language barrier were
excluded from the analysis, the association between ECM
level and treatment non-completion was strengthened
with patients in ECM levels 1, 2 and 3 significantly less
likely to complete treatment in 12 months than patients in
ECM 0 (Additional file 1 Table S1).
Discussion
The main findings of this study were that: 1. Quantifying
the need for ECM using a nurse-led ECM level classifi-
cation system was feasible as part of TBCA; 2. Social
and clinical complexity and the need for ECM of TB pa-
tients in the North West was high; 3. More complex pa-
tients in higher ECM levels are more likely to have poor
treatment outcomes.
TBCA is a process that goes beyond simply evaluating
the care of patients; it ensures the follow-up of every TB
patient in an area, improves the quality of patient informa-
tion and enhances patient treatment [7]. In addition, TBCA
provides a forum for open discussion of the management
of individual TB cases, for obtaining peer support on the
management of complex cases, such as those with multiple
drug resistance (MDR) or non-adherence, for identification
of systemic issues and for further education of staff in TB
management and control. TBCA has been very well re-
ceived by staff in the North West of England where staff
have described TBCA as a valuable “community of prac-
tice” that has led to mutual respect and a shared sense of
purpose between staff from different disciplines [13].
TBCA meetings often involve discussion of the difficul-
ties patients face in completing a long and intensive
course of treatment and the challenges staff face in man-
aging complex patients. This, combined with the robust
data collection process central to TBCA, meant it was an
ideal vehicle to use to begin to understand the complexity
of TB cases and the need for ECM in the region. To our
knowledge this is the first time that the need for ECM has
been comprehensively quantified based on different levels
of clinical and social complexity of TB cases. In 2012
Gebril et al. performed a retrospective review of case notes
in an inner city cohort in the North West in order to esti-
mate the numbers of TB patients qualifying for ECM.
They identified 96/170 (56%) as ECM cases based on
medical and/or nursing needs, slightly below our overall
ECM estimate of 64% [14]. The more detailed and nu-
anced ECM classification system combined with the fact
that the need for ECM is assessed by the patients’ own TB
nurse is likely to account for this difference and is there-
fore likely to be a more accurate measure of the need for
ECM in the area.
The results of this study suggest that social and clinical
complexity of TB patients in the North West of England is
common and the need for ECM is high, with only 36%
assessed as ECM 0 or Standard Case Management (SCM),
leaving 64% assessed as requiring some level of ECM of
whom 14% required ECM 3 due to very complex clinical
and/or social issues impacting on treatment. The Royal
College of Nursing and the National Institute for Health
and Care Excellence (NICE) have previously recommended
at least one whole-time equivalent TB case manager per 20
incident cases requiring enhanced case management and
one per 40 incident cases requiring standard case manage-
ment [8, 11]. Therefore knowledge of the numbers requir-
ing ECM will be important in informing commissioning
decisions and ensuring TB prevention and control services
are effective in meeting the needs of patients. In addition,
as TB incidence in low burden settings is decreasing we are
likely to see increasing complexity of patients and we will
need to be adept at addressing their needs in order to suc-
cessfully manage them through to treatment completion
and prevention of further transmission. The ECM classifi-
cation scale will provide a valuable means of monitoring
the levels of complexity as the balance begins to shift.
The association between clinical and social complexity,
as measured by ECM level, and poor treatment outcome
emphasises the importance of having systems in place to
Table 4 Association between ECM level and treatment completion within 12 monthsa (N = 1493)
Single variable analysis Multivariable analysis
ECM level Total Completed treatment within 12 months a(%) OR 95% CI aORb (95% ci) 95% CI
0 553 520 (94.0) 1 1
1 481 439 (91.3) 0.66 0.41–1.06 0.67 0.40–1.12
2 269 237 (88.1) 0.47 0.28–0.78 0.47 0.27–0.84
3 190 146 (76.8) 0.21 0.13–0.34 0.23 0.13–0.41
aIf not drug resistant organism, post-mortem diagnosis or CNS disease
bOdds ratios are adjusted for age group, gender, UK born status, deprivation quintile and ethnic group
Chi-square test for trend p < 0.001
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effectively manage complex patients. In order for ECM
services to be effective, TB nurses need to be equipped
with the appropriate skills to effectively manage complex
patients and there should be established links and prompt
access to allied professionals who can support TB profes-
sionals in addressing housing, financial, asylum, immigra-
tion, alcohol and drug dependency and other health and
social care needs [8, 11]. Directly Observed Treatment
(DOT) should also be considered as part of ECM [12]
however DOT alone is not necessarily a solution for poor
adherence [15] and the appropriateness of providing DOT
is a decision that needs to be considered by the clinical
team. Such systems are already in place in the North West
of England however it is unclear from these data what
effect they are already having on treatment outcomes.
Further research is warranted to explore in depth the
specific challenges patients in these high risk groups face
in completing treatment and to determine where improve-
ments can be made in the services currently in place for
the management of complex patients in order to improve
treatment outcomes in the future.
Strengths and limitations
This study used data from the national Enhanced TB
Surveillance system and from TBCA; robust processes that
collect data on all TB cases in the region. Through the
TBCA process we were able to obtain data on several clin-
ical and social factors that have not been systematically
collected previously. During TBCA a concerted effort is
made to optimise the completeness and quality of collected
data by amending any inaccuracies as cases are presented.
There were a number of limitations of the study. The
ECM level categorisation is a subjective and unvalidated
process for measuring the extra support a patient requires
from the TB nurse and allocation to ECM level is based on
their professional judgement. However, in order to maintain
consistency, ECM classifications are discussed at TBCA
meetings where reasons for the chosen ECM level are justi-
fied. Case complexity is not a clearly defined issue and its
definition will inevitably remain in part a subjective process.
It will depend on the skills of, and resources available to, the
TB case manager; and at a population level it will depend
on the characteristics of the population served. For example
in the North West, language barrier is a major factor affect-
ing case complexity but this may not be the case in other
areas either in terms of the demographics of the population
or in terms of the language skills of the TB case managers.
Therefore, although the specific results from the North
West of England are not directly generalizable to other
regions, the methods used in the North West are poten-
tially generalizable to other areas in the UK and in Eur-
ope that have introduced or are considering introducing
TBCA as part of their TB prevention and control strat-
egies. The ECM classification system presented can be
adapted by service providers to represent the needs of
their population and the skills and resources available to
the local TB workforce and analysed accordingly.
Future work could explore approaches to evaluate case-
complexity more objectively and allow comparison between
different areas. This may include measuring individual
social and clinical factors in more detail and determining
their relative importance in influencing both the amount of
input required from the TB specialist nurses and treatment
outcome using methods such as multivariable analysis or
propensity analysis.
ECM scores are representative of the level of clinical
and social complexity of patients and we have demon-
strated that higher levels of complexity are associated
with poorer treatment outcomes. This relationship is
likely to be mitigated by the fact that patients in higher
ECM levels, by the very nature of the classification, will
receive a higher level of input and support from the
multidisciplinary team leading to an underestimate of
the association between clinical and social complexity
and treatment outcome. Conversely, although ECM
levels are considered early on in a patient’s treatment,
they may be dynamic, evolving with a patient’s needs,
and reflect the level of care ultimately required rather
than that initially envisaged. Due to the retrospective op-
erational nature of the study and the lack of independent
validation of the ECM level assigned there is a possibility
that the ECM level reported at the time of TBCA may be in-
fluenced, consciously or subconsciously, by knowledge of
treatment outcome; potentially leading to an overestimation
of the association between clinical and social complexity
and treatment outcome.
Finally, the ECM classification system will be useful in
informing commissioning decisions, particularly in rela-
tion to workforce capacity, however it only reflects cases
of active TB and the needs of cases of latent TB infec-
tion (LTBI) will also need to be considered in optimising
prevention and control services.
Conclusions
Quantifying the need for ECM through nurse-led classi-
fication as part of regional Cohort Audit is feasible and
has demonstrated that clinical and social complexity in
TB patients in the North West of England and the need
for ECM is high. The uses of TBCA go beyond simply
auditing performance outcomes and the process can be
harnessed to further understand ECM requirements and
inform workforce capacity planning, training and service
development in the region to improve the management
of complex patients in the future.. The ECM classifica-
tion system could be expanded and adapted to other re-
gions where TBCA has been established as part of TB
prevention and control.
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Additional file
Additional file 1: Table S1. Association between ECM level and treatment
completion within 12 months† excluding patients recorded as having a language
barrier (N=1194) (DOCX 12 kb)
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Table 5 Guide to classification of patients to Enhanced Case Management levels used in TBCA
ECM level Clinical factors TB specific Social factors
0 Physically able to self-medicate
No central nervous system impairment
Positive IsoScreen at reviews
Correct tablet count at reviews
Contact tracing requirements limited
to adults in the same household
No stigma related issues
No language barriers
No housing or finance issues
impacting on treatment
1 Elderly to monitor for side effects
Children to ensure compliance of
child and parent/carer
Requires GP or community
pharmacy input for blister packs to
check correct doses
Taking complex medications e.g.
HIV medications
Disease site e.g. smear positive
pulmonary or central nervous
system disease
Contact tracing requirements in
various areas and/or settings e.g.
patient out of area, workplace,
community group settings
Stigma that can be dealt with
through one-to-one education
Requires interpreter for first visit but
has some understanding of English
Requires signposting for benefits
and/or financial issues
Patient difficult to reach e.g. no front
door bell, more than 1 address, problems
getting time off work/college,
refusal of home visits
2 Having complex side effects
requiring LFT monitoring
Needs more regular prompting with
medications e.g. blister packs,
regular IsoScreen, tablet counts
HIV and TB co-infection and
starting both anti-retroviral and TB
medications at the same time
Single drug resistance
Transmission within contacts or
children who are contacts
Stigma that requires more formal
education e.g. through community
centres or workplaces
Financial difficulties that may affect
treatment compliance e.g. attending
clinic, poor nutrition, poor heating
Language barriers throughout
treatment requiring easily accessible
interpreter at each visit either face to
face or by phone
Alcohol and/or drug dependency
without LFT derangement
Patient difficult to reach e.g. DNA at
clinics, not home for reviews
3 More than one drug resistance
Needs reintroduction of
medications e.g. due to deranged LFT’s
Complex contact tracing e.g.
transmission to children, vulnerable
groups, extensive transmission
Involvement of PHE for workplace
or community screening
Difficult language barriers throughout
treatment
Homelessness or housing issues due to finance
Illegal immigrants, difficulty accessing benefits
Potentially dangerous patients where
more than one person is required to visit
Children who DNA and where social
service involvement is required
Patient difficult to reach e.g. consistent
DNA at clinics, consistently not home
for reviews
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